Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 8/20 | 0.51 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20999704 | 1.00 | ATF4 (0.51) | ATF4ADAMTS5SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL20999107 | 1.00 | ATF4 (0.51) | ATF4ADAMTS5SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL20999264 | 0.96 | ATF4 (0.54) | ATF4ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL20999273 | 0.96 | ATF4 (0.54) | ATF4ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL20999664 | 0.96 | ATF4 (0.54) | ATF4ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL20999239 | 0.94 | ATF4 (0.52) | ATF4ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL20999084 | 0.94 | ATF4 (0.51) | ATF4ALDH1A1LMNATP53THRB | |
| SCHEMBL20999249 | 0.94 | ATF4 (0.51) | ATF4ALDH1A1LMNATP53THRB | |
| SCHEMBL22669272 | 0.94 | ATF4 (0.51) | ATF4ALDH1A1LMNATP53THRB | |
| SCHEMBL22669409 | 0.93 | LMNA (0.47) | ATF4ADAMTS5SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885ADAMTS5 4728/4885SMN1; SMN2 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.